What is the AQUAx2 Study?

The AQUAx2 study is a clinical research study for people with moderate or severe dry mouth (xerostomia) caused by radiation therapy for head and neck cancer. The purpose of this study is to assess the efficacy and safety of a new investigational gene transfer study drug, called AAV2-hAQP1, in helping with dry mouth resulting from radiation damage to the salivary glands.

Learn More

Who can participate in the AQUAx2 Study?

People who have too little saliva because they have received radiation therapy for head and neck cancer must meet certain criteria to qualify for the study. If you are interested, review the criteria listed below under “Who can participate in the study?” and then answer the questions under “Do You Qualify”. If your answers qualify you to go on to the next step, a delegate will reach out to you to schedule a screening visit with a clinical trial site near you to determine if you fully qualify for the study.

Learn More

What is Xerostomia?

Xerostomia (dry mouth) is a condition in which a person’s salivary glands do not produce enough saliva. Symptoms include difficulty eating, chewing, and speaking, oral pain, sore throat, difficulty sleeping, inability to exercise, uncontrollable dental caries (tooth decay) and inability to wear dentures, yeast infections, and oral burning. It can be caused by damage from radiation therapy for head and neck cancer. Currently, there is no treatment for people with moderate or severe xerostomia.

Learn More

Visit our Frequently Asked Questions page

If you have more questions or would like to explore online resources with useful information, visit our Resources page.

Ways to get in touch with us.